CCCC — C4 Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-10-02.
Performance
Technicals
Others in Healthcare
Measured signals that fired on CCCC
| date | signal | measured base rate |
|---|---|---|
| 2026-08-14 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-05-13 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-03-09 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-02-26 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-10 | REYNO LEONARD Chief Medical Officer | Shares withheld for tax | 7.4K | 4.06 | 30.0K |
| 2026-07-10 | REYNO LEONARD Chief Medical Officer | Option exercise | 15.3K | 0.00 | 0 |
| 2026-07-01 | GROGAN DONNA ROY Director | Grant or award | 3.3K | 4.34 | 14.5K |
| 2026-07-01 | Anderson Kenneth Carl Director | Grant or award | 2.6K | 4.34 | 11.5K |
| 2026-06-01 | Anderson Kenneth Carl Director | Option exercise | 1.1K | 2.11 | 2.3K |
| 2026-04-01 | GROGAN DONNA ROY Director | Grant or award | 5.4K | 2.70 | 14.5K |
| 2026-04-01 | Anderson Kenneth Carl Director | Grant or award | 4.3K | 2.70 | 11.5K |
| 2026-02-15 | Hirsch Andrew President & CEO | Shares withheld for tax | 9.1K | 1.89 | 17.1K |
| 2026-02-15 | Hirsch Andrew President & CEO | Option exercise | 20.4K | 0.00 | 0 |
| 2026-02-14 | Hirsch Andrew President & CEO | Shares withheld for tax | 39.2K | 1.89 | 74.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| MORGAN STANLEY | 23.9M | 9.1M |
| RA CAPITAL MANAGEMENT, L.P. | 21.0M | 8.0M |
| Bain Capital Life Sciences Investors, LLC | 18.9M | 7.2M |
| Lynx1 Capital Management LP | 18.4M | 7.0M |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.2M | 3.9M |
| Soleus Capital Management, L.P. | 10.0M | 3.8M |
| TWO SIGMA INVESTMENTS, LP | 8.0M | 3.0M |
| WASATCH ADVISORS LP | 7.8M | 3.0M |
| JPMORGAN CHASE & CO | 7.6M | 3.2M |
| CITADEL ADVISORS LLC | 6.6M | 2.5M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Why is C4 Therapeutics stock gaining today? · 2026-08-11
- C4 Therapeutics, Inc. (CCCC) filed form 8-K · 2026-08-11 · SEC EDGAR
- C4 Therapeutics GAAP EPS of -$0.18 beats by $0.05, revenue of $6.64M beats by $2.64M · 2026-08-11
Ask the AI about CCCC
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →